Clinical trials: Severe Cardiomyopathy
COVID-19, Myocardial Reperfusion Injury
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system.
- Conditions
- COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
- Trial name
- NCT04397939
- Where
- United States
- Volunteers
- 4,695 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited